TAMPA, FL / ACCESSWIRE / March 27, 2023 / TRxADE HEALTH, INC. (NASDAQ:MEDS) ("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced its financial results for the year ended December 31, 2022.
2022 and Subsequent Operational Highlights
TRxADE continued to expand the TRxADE drug procurement marketplace nationwide, adding 1,212 new registered members during fiscal 2022, bringing the total registered members to approximately 14,400+ at December 31, 2022.
Management Commentary
Mr. Ajjarapu commented, "2022 was an exciting and challenging time for TRxADE. We continue to focus the Company's strategic plans and partnerships, working towards creating sustainable value for our stockholders. I am pleased with the growth we have experienced in our TRxADE platform. We continue to achieve key milestones in our internal roadmap with a focus on innovation and development through our various complementary growth opportunities."
2022 Annual Financial Summary
Consolidated revenues for the fiscal year of 2022 compared to the fiscal year of 2021 increased 16% to $11.4 million, compared to $9.9 million, respectively. The increase in consolidated revenue was driven by improved revenue attributed to our TRxADE Platform and Trxade Prime subsidiaries. The revenues generated by the TRxADE Platform in the fiscal year 2022 compared to 2021 increased 10% and Trxade Prime year over year revenue improved 46% in 2022 compared to 2021. The subsidiary company Community Specialty Pharmacy experienced a 29% decrease in revenue for the fiscal year 2022 compared to 2021.
Gross profit analysis of comparable fiscal periods of 2022 and 2021 reflect an increase in gross profits of $0.7 million for the fiscal year of 2022 compared to 2021. As a percent of revenue, consolidated gross profit remained consistent at 48% for the comparable annual periods of 2022 and 2021.
Operating expenses for the fiscal year of 2022 were $9.9 million, compared to $10 million in the fiscal year 2021.
Net loss for the year ended December 31, 2022, was ($3.9) million, or ($0.41) per basic and diluted share outstanding, compared to a net loss of ($5.3) million, or ($0.65) per basic and diluted share outstanding for same period in 2021.
Adjusted EBITDA, a non-GAAP financial measure, was ($0.09) million for the fiscal year 2022, compared to ($3.1) million for the fiscal year 2021. See "Use of Non-GAAP Financial Information" below, and the reconciliation of Adjusted EBITDA to GAAP set forth at the end of this release.
Additional metrics related to our key performance are as follows:
For the twelve-month period ended December 31, 2022, the TRxADE Platform increased its registered users by 8%. Total registered users increased to approximately 14,400+ from 13,100+, as of December 31, 2022, and 2021, respectively. For the same comparable periods the TRxADE Platform revenues increased 10% from $4.9 million for the year ended 2021 to $5.4 million for the year ended 2022. Sales volume on the TRxADE Platform also increased year over year by 17% for the comparable fiscal years.
For the twelve-month period ended December 31, 2022, compared to the same period in 2021, Integra Pharma Solutions, LLC ("TRxADE Prime") revenue improved 46% from $3.2 million to $4.8 million.
TRxADE Prime also saw improvements in gross margin. For the fiscal year 2022 gross margin was a positive 1% compared to a negative (12%) for the fiscal year 2021.
The Company is committed to continued efforts designed to build a strong foundation for Trxade Prime and further growth.
Conference Call and Webcast
Management will host a conference call on Monday, March 27, 2023, at 5:30 p.m. Eastern time to discuss TRxADE's 2022 financial results. The call will conclude with Q&A from participants. To participate, please use the following information:
2022 Conference Call and Webcast
Date: Monday, March 27, 2023
Time: 5:30 p.m. Eastern time
U.S. Dial-in: 1-877-425-9470
International Dial-in: 1-201-389-0878
Webcast: https://callme.viavid.com/viavid/?callme=true&passcode=13711397&h=true&info=company&r=true&B=6
Please dial in at least 10 minutes before the start of the call to ensure timely participation.
A playback of the call will be available through April 27, 2023. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally and enter replay pin number 13737052. A webcast will also be available for 30 days on the IR section of the Trxade Group website or by clicking the webcast link above.
About TRxADE HEALTH, INC.
TRxADE HEALTH (NASDAQ: MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace serving approximately 14,400+ members nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric telehealth services. For more information on TRxADE HEALTH, please visit the Company's IR website at investors.trxadegroup.com.
Use of Non-GAAP Financial Information
In addition to our results calculated under generally accepted accounting principles in the United States ("GAAP"), in this earnings release we also present EBITDA and Adjusted EBITDA which are "non-GAAP financial measures" presented as supplemental measures of the Company's performance. They are not presented in accordance with GAAP. EBITDA represents net income (loss) attributable to TRxADE before interest, taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA before stock-based compensation expense, bad debt recovery, bad debt write-off, gain (loss) on disposal of asset, litigation expenses, loss (gain) on inventory investment, loss (gain) on impairment of intangible asset and change in fair value of warrant liability. EBITDA and Adjusted EBITDA are presented because we believe they provide additional useful information to investors due to the various noncash items during the period. EBITDA and Adjusted EBITDA are also frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our business. EBITDA and Adjusted EBITDA have limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of our operating results as reported under GAAP. Some of these limitations are EBITDA and Adjusted EBITDA do not reflect cash expenditures, future requirements for capital expenditures, or contractual commitments; EBITDA and Adjusted EBITDA do not reflect changes in, or cash requirements for, working capital needs; and EBITDA and Adjusted EBITDA do not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on debt or cash income tax payments. Although depreciation and amortization are noncash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect any cash requirements for such replacements. Additionally, other companies may calculate EBITDA and Adjusted EBITDA differently than TRxADE does, limiting its usefulness as a comparative measure. EBITDA and Adjusted EBITDA are not recognized in accordance with GAAP, are unaudited, and have limitations as analytical tools, and you should not consider them in isolation, or as substitutes for analysis of the Company's results as reported under GAAP. The Company's presentation of these measures should not be construed as an inference that future results will be unaffected by unusual or nonrecurring items. We compensate for these limitations by providing a reconciliation of each of these non-GAAP measures to the most directly comparable GAAP measure. We encourage investors and others to review our business, results of operations, and financial information in their entirety, not to rely on any single financial measure, and to view these non-GAAP measures in conjunction with the most directly comparable GAAP financial measure. For more information on these non-GAAP financial measures, please see the section titled "Reconciliation of Net Income (Loss) attributable to TRxADE HEALTH, INC., to Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA", included at the end of this release.
Forward-Looking Statements
This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; the fact that we are exploring strategic alternatives for our Bonum Health, Inc. subsidiary; our ability to maintain the listing of our common stock on the Nasdaq Capital Market, including our current non-compliance with the continued listing standards of the Nasdaq Capital Market; risks associated with our operations not being profitable; the commercial viability of new business lines, applications, products and technologies, and the costs of such items; the Company's stock repurchase program; the adoption of the Company's product offerings; claims relating to alleged violations of intellectual property rights of others; our ability to monetize our technological solutions; technical problems with our websites, apps and products; risks relating to implementing our acquisition strategies; challenges to the pharmaceutical supply chain posed by the COVID-19 pandemic or similar events and related matters; our ability to manage our growth; negative effects on our operations associated with the opioid pain medication health crisis; regulatory and licensing requirement risks; risks related to changes in the U.S. healthcare environment; the status of our information systems, facilities and distribution networks; risks associated with the operations of our more established competitors; regulatory changes; existing and new competitors which may have more resources than we do; increases in direct to consumer sales of drugs; healthcare fraud; COVID-19, governmental responses thereto, economic downturns and increased inflation and possible recessions caused thereby; changes in laws or regulations relating to our operations; privacy laws; system errors; dependence on current management; our growth strategy; dilution which may be caused by future offerings; increased inflation and interest rates, including the increased costs of raising funding as a result thereof; and supply chain issues caused by among other things, recessions and global conflicts. Additional information about these and other factors that could cause the Company's results to differ materially from these forward-looking statements can be found in the Company's filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2022, which are available at www.sec.gov and in the "NASDAQ:MEDS" - "SEC Filings" section of the Company's website at https://www.investors.trxadehealth.com. Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Investor Relations:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors.trxadegroup.com
TRxADE HEALTH, INC.
Consolidated Balance Sheets
| December 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
Assets | ||||||||
Current Assets | ||||||||
Cash | $ | 1,133,633 | $ | 3,122,578 | ||||
Accounts receivable, net | 728,964 | 978,973 | ||||||
Inventory | 119,582 | 56,279 | ||||||
Prepaid assets | 110,944 | 216,414 | ||||||
Total Current Assets | 2,093,123 | 4,374,244 | ||||||
Property plant and equipment, net | 65,214 | 98,751 | ||||||
Intangible assets and capitalized software, net | 450,845 | - | ||||||
Deposits | 49,029 | 60,136 | ||||||
Operating lease right-of-use assets | 1,051,815 | 1,233,033 | ||||||
Total Assets | $ | 3,710,026 | $ | 5,766,164 | ||||
Liabilities and Shareholders' Equity | ||||||||
Current Liabilities | ||||||||
Accounts payable | 729,153 | 477,028 | ||||||
Accrued liabilities | 290,013 | 270,437 | ||||||
Other current liabilities | 67,517 | - | ||||||
Contingent funding liabilities | 108,036 | - | ||||||
Current portion lease liabilities | 196,872 | 178,561 | ||||||
Warrant liability | 588,533 | - | ||||||
Notes payable-- related party | 166,667 | - | ||||||
Total Current liabilities | 2,146,791 | 926,026 | ||||||
Long Term Liabilities | ||||||||
Other long-term liabilities --- leases | 887,035 | 1,069,965 | ||||||
Notes payable- related party | 333,333 | - | ||||||
Total Liabilities | 3,367,159 | 1,995,991 | ||||||
Stockholders' Equity | ||||||||
Series A preferred stock, $0.00001 par value; 10,000,000 shares authorized; none issued and outstanding, as of December 31, 2022 and December 31, 2021. | - | - | ||||||
Common stock, $0.00001 par value; 100,000,000 shares authorized; 9,393,708, and 8,166,457 shares issued and outstanding, as of December 31, 2022 and December 31, 2021, respectively | 99 | 82 | ||||||
Additional paid-in capital, net of stock issuance costs | 20,482,573 | 20,017,528 | ||||||
Retained deficit | (19,719,536 | ) | (16,247,437 | ) | ||||
Total | 763,136 | 3,770,173 | ||||||
Non-controlling interest in subsidiary | (420,269 | ) | - | |||||
Total stockholders' equity | 342,867 | 3,770,173 | ||||||
Total Liabilities and Stockholders' Equity | $ | 3,710,026 | $ | 5,766,164 | ||||
TRxADE HEALTH, INC.
Consolidated Statements of Operations
| Years Ended December 31, | ||||||||
| 2022 | 2021 | |||||||
Revenues | $ | 11,448,265 | $ | 9,889,433 | ||||
Cost of Sales | 5,997,049 | 5,143,468 | ||||||
Gross Profit | 5,451,216 | 4,745,965 | ||||||
Operating Expenses: | ||||||||
Impairment of intangible asset | 792,500 | - | ||||||
Loss on inventory investment | 875,250 | 1,226,426 | ||||||
Loss on write-down of Inventory | - | 376,348 | ||||||
Wage and salary expense | 3,941,475 | 3,846,522 | ||||||
Professional fees | 519,642 | 1,094,917 | ||||||
Accounting and legal expense | 830,355 | 697,825 | ||||||
Technology expense | 1,160,856 | 899,705 | ||||||
General and administrative | 1,755,433 | 1,896,515 | ||||||
Total operating expenses | 9,875,511 | 10,038,258 | ||||||
Operating Loss | (4,424,295 | ) | (5,292,293 | ) | ||||
Nonoperating income (expense) | ||||||||
Change in fair value of warrant liability | 825,544 | - | ||||||
Interest income | 20,989 | - | ||||||
Gain on disposal of asset | 4,100 | - | ||||||
Interest expense | (336,206 | ) | (23,590 | ) | ||||
Total nonoperating expense | 514,427 | (23,590 | ) | |||||
Net Loss | $ | (3,909,868 | ) | $ | (5,315,883 | ) | ||
Net loss attributable to TRxADE Health, Inc. | (3,472,099 | ) | (5,315,883 | ) | ||||
Net loss attributable to non-controlling interests | (437,769 | ) | - | |||||
Net loss per common share -- basic and diluted | $ | (0.41 | ) | $ | (0.65 | ) | ||
Weighted average common shares outstanding - basic and diluted | 8,472,946 | 8,136,740 | ||||||
TRxADE HEALTH, INC.
Consolidated Statements of Cash Flows
| Years Ended December 31, | ||||||||
| 2022 | 2021 | |||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (3,909,868 | ) | $ | (5,315,883 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation expense | 14,637 | 7,351 | ||||||
Options expense | 79,163 | 187,273 | ||||||
Common stock issued for services | 254,121 | 181,163 | ||||||
Bad debt expense | (246,683 | ) | 615,657 | |||||
Warrant Expense | - | 21,640 | ||||||
Loss on write-off of intangible asset | 792,500 | - | ||||||
Loss on write-down of Inventory | 875,250 | 376,348 | ||||||
Loss on inventory investments | - | 143,891 | ||||||
Gain on sale of asset | (4,100 | ) | - | |||||
Amortization of right of use assets | 181,218 | 131,558 | ||||||
Changes in operating assets and liabilities: | ||||||||
Deferred offering costs | - | - | ||||||
Accounts receivable, net | 496,692 | (789,587 | ) | |||||
Prepaid assets and deposits | 336,928 | (103,666 | ) | |||||
Inventory | (63,303 | ) | 825,127 | |||||
Other receivables | (875,250 | ) | 1,087,675 | |||||
Lease liability | (164,618 | ) | (131,153 | ) | ||||
Accounts payable | 252,125 | 220,199 | ||||||
Accrued liabilities | (200,776 | ) | (13,819 | ) | ||||
Current liabilities | 67,517 | - | ||||||
Warrant liability | 588,533 | - | ||||||
Customer Deposits | - | (10,000 | ) | |||||
Net cash used in operating activities | (1,525,929 | ) | (2,566,226 | ) | ||||
Cash flows from investing activities: | ||||||||
Purchase of fixed assets | - | (22,596 | ) | |||||
Sale of fixed assets | 23,000 | - | ||||||
Investment in capitalized software | (450,845 | ) | - | |||||
Net cash used in investing activities | (427,845 | ) | (22,596 | ) | ||||
Cash flows from financing activities: | ||||||||
Repayments of Promissory Notes - Related Parties | - | (225,000 | ) | |||||
Repayment of contingent liability | (716,964 | ) | - | |||||
Distributions to non-controlling interest | (275,000 | ) | - | |||||
Proceeds from sale of future revenue | 825,000 | - | ||||||
Proceeds from exercise of stock options | - | 1,821 | ||||||
Proceeds from exercise of warrants | 875 | 15,001 | ||||||
Proceeds from issuance of common stock, net offering costs | 130,903 | - | ||||||
Valuation of warrant | - | - | ||||||
Net cash provided by financing activities | (35,171 | ) | (208,178 | ) | ||||
Net decrease in cash | (1,988,948 | ) | (2,797,000 | ) | ||||
Cash at beginning of the year | 3,122,578 | 5,919,578 | ||||||
Cash at end of the period | $ | 1,133,633 | $ | 3,122,578 | ||||
Supplemental disclosure of cash flow information | ||||||||
Cash paid for interest | $ | 336,206 | $ | 28,337 | ||||
Cash paid for income taxes | $ | - | $ | - | ||||
Non-Cash Transactions | ||||||||
Insurance premium financed | $ | 220,354 | $ | - | ||||
Note issued as SOSRx contribution | $ | 500,000 | $ | - | ||||
Intangible asset contribution from non-controlling interest | $ | 792,500 | $ | - | ||||
Reconciliation of Net Income (Loss) attributable to TRxADE HEALTH, Inc., to Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA*
| Years Ended December 31, | ||||||||
| 2022 | 2021 | |||||||
Net loss attributable to TRxADE Health, Inc. | $ | (3,472,095 | ) | $ | (5,315,883 | ) | ||
Add (deduct): | ||||||||
Interest, net | 315,217 | 23,590 | ||||||
Depreciation and amortization | 15,113 | 7,351 | ||||||
EBITDA * | (3,141,765 | ) | (5,284,942 | ) | ||||
Add (deduct): | ||||||||
Bad debt recovery | 247,861 | - | ||||||
Change in fair value of warrant liability | 825,544 | - | ||||||
Impairment of intangible asset | 792,500 | - | ||||||
Bad debt write off | (247,867 | ) | 630,000 | |||||
Loss on inventory investment | 875,250 | 1,225,141 | ||||||
Gain on disposal of asset | (4,100 | ) | - | |||||
Litigation expenses | 225,000 | - | ||||||
Stock-based compensation | 333,269 | 368,436 | ||||||
Adjusted EBITDA * | $ | (94,307 | ) | $ | (3,061,365 | ) | ||
* EBITDA and Adjusted EBITDA are non-GAAP financial measures. These measurements are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance. See also "Use of Non-GAAP Financial Information", above.
| Last Trade: | US$7.46 |
| Daily Volume: | 10,853 |
July 26, 2024 October 12, 2023 August 22, 2023 August 03, 2023 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
